Antileukemic effect of daclizumab in CD25 high-expressing leukemias and impact of tumor burden on antibody dosing

Leukemia Research

Volumn 30, Issue 2, 2006, Pages 190-203

  Koon, H B ^a   Severy, P ^a   Hagg, D S ^a   Butler, K ^a   Hill, T ^a   Jones, A G ^b   Waldmann, T A ^c   Junghans, R P ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

Antibody; HAT; Humanized; Tac

Indexed keywords

ANTILEUKEMIC AGENT; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ALPHA;

ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT DISORDER; BONE PAIN; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; COUGHING; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; FATIGUE; FEMALE; FEVER; HUMAN; HYPERTENSION; LEUKEMIA; MALE; PRIORITY JOURNAL; RASH; TARGET CELL DESTRUCTION; TUMOR LYSIS SYNDROME; TUMOR VOLUME; VERTIGO; WEIGHT REDUCTION;

ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INDIUM RADIOISOTOPES; LEUKEMIA; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTORS, INTERLEUKIN-2;

EID: 28844471518     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.06.007     Document Type: Article

References (26)

1. T.A. Waldmann, I.H. Pastan, O.A. Gansow, and R.P. Junghans The multichain interleukin-2 receptor: a target for immunotherapy Ann Intern Med 116 1992 148 160
2. C. Queen, W.P. Schneider, H.E. Selick, P.W. Payne, N.F. Landolfi, and J.F. Duncan A humanized antibody that binds to the interleukin 2 receptor Proc Natl Acad Sci USA 86 1989 10029 10033
3. R.P. Junghans, T.A. Waldmann, N.F. Landolfi, N.M. Avdalovic, W.P. Schneider, and C. Queen Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders Cancer Res 50 1990 1495 1502
4. T.A. Waldmann, J.D. White, C.K. Goldman, L. Top, A. Grant, and R. Bamford The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia Blood 82 1993 1701 1712
5. T.A. Waldmann, J.D. White, J.A. Carrasquillo, J.C. Reynolds, C.H. Paik, and O.A. Gansow Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac Blood 86 1995 4063 4075
6. T.J. Lehky, M.C. Levin, R. Kubota, R.N. Bamford, A.N. Flerlage, and S.S. Soldan Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac Ann Neurol 44 1998 942 947
7. C.B. Carpenter, R.L. Kirkman, M.E. Shapiro, E.L. Milford, N.L. Tiney, and T.A. Waldmann Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation Am J Kidney Dis 14 1989 54 57
8. F. Vincenti, R. Kirkman, S. Light, G. Bumgardner, M. Pescovitz, and P. Halloran Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group N Engl J Med 338 1998 161 165
9. R.W. Kozak, A. Raubitschek, S. Mirzadeh, M.W. Brechbiel, R.P. Junghans, and O.A. Gansow Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicity Cancer Res 49 1989 2639 2644
10. R.W. Kozak, D.P. Fitzgerald, R.W. Atcher, C.K. Goldman, D.L. Nelson, and O.A. Gansow Selective elimination in vitro of alloresponsive T cells to human transplantation antigens by toxin or radionuclide conjugated anti-IL-2 receptor (Tac) monoclonal antibody J Immunol 144 1990 3417 3423
11. D.S. Hagg, and R.P. Junghans Measurement and biological correlates of antibody bioactivity during antibody immunotherapies J Immunol Methods 219 1998 7 21
12. R.P. Junghans The Brambell receptor (FcRB) and the biological half-life of clinical antibodies Blood Bone Mar Transpl 9 1999 667 679
13. A. Morell, W.D. Terry, and T.A. Waldmann Metabolic properties of IgG subclasses in man J Clin Invest 49 1970 673 680
14. R.P. Junghans Leukemia is a disease of the marrow. Images in Clinical Medicine N Engl J Med 339 1998 1375
15. R.P. Junghans, J.A. Carrasquillo, and T.A. Waldmann Impact of antigenemia on the bioactivity of infused anti-Tac antibody: implications for dose selection in antibody immunotherapies Proc Natl Acad Sci USA 95 1998 1752 1757
16. R.P. Junghans, and T.A. Waldmann Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding J Exp Med 183 1996 1587 1602
17. R.P. Junghans, A. Stone, and M.S. Lewis Biophysical characterization of a recombinant soluble interleukin 2 receptor (Tac): evidence for a monomeric structure J Biol Chem 271 1996 10453 10460
18. D.B. Scheinberg, G. Sgouros, and R.P. Junghans Antibody-based immunotherapies for cancer B.A. Chabner DL. Longo Cancer chemotherapy and biotherapy: principles and practice 3rd ed. 2001 Lippincott Philadelphia 850 890 [chapter 29]
19. R.P. Junghans A strategy for evaluating lymphokine activation and novel monoclonal antibodies in antibody-dependent cell-mediated cytotoxicity and effector cell retargeting assays Cancer Immunol Immunother 31 1990 207 212
20. T.A. Waldmann, C. Goldman, L. Top, A. Grant, J. Burton, and R. Bamford The interleukin-2 receptor: a target for immunotherapy Adv Exp Med Biol 323 1992 57 66
21. R.P. Junghans, and Y.S. Ahn High-dose intravenous gamma globulin to suppress alloimmune destruction of donor platelets Am J Med 76 1984 204 208
22. M.J. Dyer, G. Hale, F.G. Hayhoe, and H. Waldmann Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype Blood 73 1989 1431 1439
23. P.S. Brown Jr., G.L. Parenteau, F.M. Dirbas, R.J. Garsia, C.K. Goldman, and M.A. Bukowski Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival Proc Natl Acad Sci USA 88 1991 2663 2667
24. J. Baselga, D. Pfister, M.R. Cooper, R. Cohen, B. Burtness, and M. Bos Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin J Clin Oncol 18 2000 904 914
25. H.M. Kantarjian, M. Talpaz, K. Dhingra, E. Estey, M.J. Keating, and S. Ku Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia Blood 78 1991 2411 2418
26. D. Grimwade, H. Walker, F. Oliver, K. Wheatley, C. Harrison, and G. Harrison The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties Blood 92 1998 2322 2333